B. Ritchie

P. Keith, J. Bernstein, R. Schellenberg, 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

Experiences with continuous infusion of recombinant activated factor VII.

M. Morfini, J. Goudemand, C. Négrier, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A comparative evaluation of poly-L-lysine-palmitic acid and Lipofectamine 2000 for plasmid delivery to bone marrow stromal cells.

H. Uludaǧ, Cezary Kucharski, A. Lavasanifar, 2007, Biomaterials.

Activated prothrombin complex concentrate for dabigatran‐associated bleeding

B. Ritchie, S. Schulman, S. Nahirniak, 2014, British journal of haematology.

Use of Direct Oral Anticoagulants Versus Traditional Therapies for Acute Venous Thromboembolism After Direct Discharge From the Emergency Department or After Hospitalization: An Audit of 16 Canadian Hospitals.

B. Ritchie, T. Bungard, W. Semchuk, 2020, Clinical therapeutics.

Anticoagulant therapies for acute venous thromboembolism: a comparison between those discharged directly from the emergency department versus hospital in two Canadian cities

B. Ritchie, T. Bungard, W. Semchuk, 2018, BMJ Open.

Anticoagulant therapies for acute venous thromboembolism among a cohort of patients discharged from Canadian urban and rural hospitals

B. Ritchie, T. Bungard, W. Semchuk, 2018, BMJ Open.

Management of acute venous thromboembolism among a cohort of patients discharged directly from the emergency department

B. Ritchie, T. Bungard, W. Semchuk, 2018, BMJ Open.

Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study

Z. Fayad, S. Goldhaber, M. Mercuri, 2016, Vascular medicine.

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema.

William H. Yang, P. Keith, R. Schellenberg, 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema.

William H. Yang, H. Farkas, R. Warrington, 2004, The Journal of allergy and clinical immunology.

New Frontiers in Subcutaneous Immunoglobulin Treatment

M. Sturzenegger, B. Ritchie, M. Stein, 2011, Biologics in therapy.

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

C. Kempton, C. Kessler, B. Ritchie, 2007 .

Sustained Impact of Anticoagulant Control Achieved in an Anticoagulation Management Service After Transfer of Management to the Primary Care Physician

R. Tsuyuki, B. Ritchie, T. Bungard, 2012, Pharmacotherapy.

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study

H. Bonkovsky, P. Stein, M. Sweetser, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Preprocedure Administration of Oral Vitamin K1: Lessons Learned from 2 Experiences in the Same Patient

B. Ritchie, T. Bungard, Anna Klakowicz, 2007 .

Efficacy and Safety of Subcutaneous Vivaglobin® Replacement Therapy in Previously Untreated Patients with Primary Immunodeficiency: A Prospective, Multicenter Study

B. Ritchie, D. S. Schmidt, I. Quinti, 2011, Journal of Clinical Immunology.

[WAO Guideline for the Management of Hereditary Angioedema].

R. Lockey, R. Pawankar, W. Lumry, 2015, Arerugi = [Allergy].

A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

L. Sehn, E. Haddad, D. Vinh, 2016, Current oncology.

First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System

A. Iorio, N. Heddle, B. Ritchie, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical perspectives of emerging pathogens in bleeding disorders

M. Diamond, P. Simmonds, S. Bozzette, 2006, The Lancet.

Protease inhibitors in the treatment of hereditary angioedema.

B. Ritchie, 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

A Canadian survey of self‐infusion practices in persons with haemophilia A

V. Blanchette, R. Klaassen, B. Ritchie, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update

R. Lockey, R. Pawankar, W. Lumry, 2018, Allergy.

Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada

V. Blanchette, N. Young, R. Klaassen, 2016, BMC Hematology.

Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia.

Sunita Ghosh, M. Mant, J. Brandwein, 2016, Leukemia research.

Clinical Efficacy , Safety and Tolerability of a New Subcutaneous Immunoglobulin 16 . 5 % ( Octanorm [ Cutaquig ® ] ) in the Treatment of Patients With Primary Immunodeficiencies

R. Kobayashi, J. Litzman, Sudhir Gupta, 2019 .

Chronic Immune Thrombocytopenic Purpura in Children: A Survey of the Canadian Experience

V. Blanchette, B. Ritchie, John Wu, 2007, Journal of pediatric hematology/oncology.

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.

J. Bernstein, B. Ritchie, T. Craig, 2009, The Journal of allergy and clinical immunology.

Repeat treatment of acute hereditary angioedema attacks with open‐label icatibant in the FAST‐1 trial

W. Lumry, B. Ritchie, J. Hébert, 2014, Clinical and experimental immunology.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

William H. Yang, P. Keith, P. Schmid‐Grendelmeier, 2010, The New England journal of medicine.

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

William H. Yang, P. Keith, P. Kralickova, 2017, The New England journal of medicine.

Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity.

J. Bernstein, B. Ritchie, T. Craig, 2011, Allergy and Asthma Proceedings.

Management of hereditary angioedema: 2010 Canadian approach

B. Ritchie, J. Hébert, T. Bowen, 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

Clinical Outcomes With Recombinant Human C1 Inhibitor In The Repeat Treatment Of Acute Attacks Of Hereditary Angioedema In North-american Patients

William H. Yang, R. Lockey, J. Bernstein, 2011 .

Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks.

J. Bernstein, B. Ritchie, T. Craig, 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

M. Triggiani, J. Bernstein, M. Gompels, 2018, Allergy.

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

William H. Yang, J. Bernstein, W. Lumry, 2023, The Lancet.

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

William H. Yang, P. Keith, W. Lumry, 2022, The Lancet.

Management of hereditary angioedema: 2010

B. Ritchie, J. Hébert, T. Bowen, 2010 .

Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence

Todor A Popov, T. Zuberbier, N. Papadopoulos, 2020, Allergy.

Interim Results of EDEMA2, a Multicenter, Open-label, Repeat-Dosing Study of Intravenous and Subcutaneous Administration of Ecallantide (DX-88) in Hereditary Angioedema

W. Lumry, B. Ritchie, T. Beck, 2006 .

Management of hereditary angioedema: a Canadian approach.

William H. Yang, R. Warrington, B. Ritchie, 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Tissue archives to track blood borne pathogens in people receiving blood products.

B. Ritchie, 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Prompt response to rituximab of severe hemolytic anemia with both cold and warm autoantibodies

M. Mant, B. Ritchie, D. Webster, 2004, American journal of hematology.

Safety and feasibility of red cell exchange for sickle cell disease across Canada.

B. Ritchie, P. Yenson, D. Barth, 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

The fludarabine, cytarabine, and granulocyte colony‐stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline‐based therapy for the treatment of acute myeloid leukemia for patients with pre‐existing cardiac disease

Sunita Ghosh, M. Mant, J. Brandwein, 2016, European journal of haematology.

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study

S. Klarenbach, B. Ritchie, H. Blain, 2022, Allergy, Asthma & Clinical Immunology.

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies

R. Kobayashi, J. Litzman, Sudhir Gupta, 2022, Clinical and experimental immunology.

Abstract 12074: A Randomized, Open-Label, Multicenter Study of the Efficacy and Safety of Edoxaban Monotherapy versus Low-Molecular Weight Heparin/Warfarin in Patients With Symptomatic Deep Vein Thrombosis - Edoxaban Thrombus Reduction Imaging Study (eTRIS)

Z. Fayad, S. Goldhaber, M. Mercuri, 2014 .

GS-14-ENVISION, a phase 3 study to evaluate efficacy and safety of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1, in acute hepatic porphyria patients

H. Bonkovsky, P. Stein, L. Gouya, 2019, Journal of Hepatology.

A Ten Year Survey of Chronic Immune Thrombocytopenic Purpura in Canadian Children, 1984–2003: Report of the Canadian Chronic ITP Working Group.

B. Ritchie, John Wu, A. Chan, 2004 .

A randomized trial of restarting warfarin at maintenance versus loading doses following an elective procedure

B. Ritchie, T. Bungard, Jay Mutch, 2017, Journal of Thrombosis and Thrombolysis.

996 Disease Characteristics of Acute Hepatic Porphyria Patients: ENVISION, a Phase 3 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

H. Bonkovsky, P. Stein, L. Gouya, 2019, American Journal of Gastroenterology.

ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY REVIEW Open Access

P. Keith, J. Bernstein, R. Schellenberg, 2022 .

Late-Onset Lymphopenia and ITP in a Patient with Hyper IgM Syndrome Due to a Homozygous Variant in AICDA.

B. Ritchie, A. Adatia, 2023, Journal of clinical immunology.

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing

B. Ritchie, A. Adatia, 2023, The journal of allergy and clinical immunology. Global.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

William H. Yang, P. Keith, P. Schmid‐Grendelmeier, 2010, The New England journal of medicine.

Efficacy And Safety Of Bradykinin B2 Receptor Inhibition With Oral PHVS416 In Treating Hereditary Angioedema Attacks: Results Of RAPIDe-1 Phase 2 Trial

William H. Yang, P. Kralickova, R. Crabbé, 2023, Journal of Allergy and Clinical Immunology.